Article thumbnail
Location of Repository

Maged1, a new regulator of skeletal myogenic differentiation and muscle regeneration

By Tuan HN Nguyen, Mathieu JM Bertrand, Christiane Sterpin, Younes Achouri and Olivier RY De Backer
Topics: Research Article
Publisher: BioMed Central
OAI identifier: oai:pubmedcentral.nih.gov:2912822
Provided by: PubMed Central

Suggested articles

Citations

  1. (1989). A new DNA binding and dimerization motif in immunoglobulin enhancer binding, daughterless, MyoD, and myc proteins. Cell
  2. (2002). A: The MAGE proteins: emerging roles in cell cycle progression, apoptosis, and neurogenetic disease.
  3. (2004). CJ: hNRAGE, a human neurotrophin receptor interacting MAGE homologue, regulates p53 transcriptional activity and inhibits cell proliferation. FEBS Lett
  4. (2008). De Backer O: NRAGE, a p75NTR adaptor protein, is required for developmental apoptosis in vivo. Cell Death Differ
  5. (1990). Differences and similarities in DNA-binding preferences of MyoD and E2A protein complexes revealed by binding site selection. Science
  6. (2005). Dynlacht BD: An initial blueprint for myogenic differentiation. Genes Dev
  7. (2008). EH: MBNL3/CHCR prevents myogenic differentiation by inhibiting MyoD-dependent gene transcription. Differentiation
  8. (2006). et al.: p53 family members in myogenic differentiation and rhabdomyosarcoma development. Cancer Cell
  9. (2009). Fang WG: MAGE-D1 inhibits proliferation, migration and invasion of human breast cancer cells. Oncol Rep
  10. (2001). Fernandez A: Crosstalk between cell cycle regulators and the myogenic factor MyoD in skeletal myoblasts. Cell Mol Life Sci
  11. (1996). Gallie BL: pRb controls proliferation, differentiation, and death of skeletal muscle cells and other lineages during embryogenesis. Genes Dev
  12. (1999). Gene targeting restricted to mouse striated muscle lineage. Nucleic Acids Res
  13. (1991). H: Functional activity of myogenic HLH proteins requires heterooligomerization with E12/E47-like proteins in vivo. Cell
  14. (2005). Human NRAGE disrupts E-cadherin/ betacatenin regulated homotypic cell-cell adhesion. Biochem Biophys Res Commun
  15. (2010). Interaction of MAGED1 with nuclear receptors affects circadian clock function.
  16. (2005). JM: NRAGE mediates p38 activation and neural progenitor apoptosis via the bone morphogenetic protein signaling cascade. Mol Cell Biol
  17. (2009). JM: NRAGE: a potential rheostat during branching morphogenesis. Mech Dev
  18. (2002). K: A RING finger protein Praja1 regulates Dlx5-dependent transcription through its ubiquitin ligase activity for the Dlx/Msx-interacting MAGE/Necdin family protein,
  19. (2003). L: UNC5H1 induces apoptosis via its juxtamembrane region through an interaction with NRAGE.
  20. (1995). Lassar AB: Correlation of terminal cell cycle arrest of skeletal muscle with induction of p21 by MyoD. Science
  21. (1997). Levrero M: p300 is required for MyoD-dependent cell cycle arrest and muscle-specific gene transcription.
  22. (2003). LM: Gene expression profiling of Duchenne muscular dystrophy skeletal muscle. Neurogenetics
  23. (2003). Minami Y: The receptor tyrosine kinase Ror2 associates with the melanoma associated antigen (MAGE) family protein Dlxin-1 and regulates its intracellular distribution.
  24. (2004). Necdin interacts with the Msx2 homeodomain protein via MAGE-D1 to promote myogenic differentiation of C2C12 cells.
  25. (2007). Necdin mediates skeletal muscle regeneration by promoting myoblast survival and differentiation.
  26. (2007). NRAGE associates with the antiapoptotic factor Che-1 and regulates its degradation to induce cell death.
  27. (2000). PA: NRAGE, a novel MAGE protein, interacts with the p75 neurotrophin receptor and facilitates nerve growth factor-dependent apoptosis. Neuron
  28. (2010). PA: ProNGF induces TNFalpha-dependent death of retinal ganglion cells through a p75NTR non-cell-autonomous signaling pathway. Proc Natl Acad Sci USA
  29. (2005). Q: BRCA2 suppresses cell proliferation via stabilizing MAGE-D1. Cancer Res
  30. (1996). Resistance to apoptosis conferred by Cdk inhibitors during myocyte differentiation. Science
  31. (1999). Roberts JM: CDK inhibitors: positive and negative regulators of G1-phase progression. Genes Dev
  32. (2001). S: An overview of the MAGE gene family with the identification of all human members of the family. Cancer Res
  33. (2009). S: Necdin is expressed in cachectic skeletal muscle to protect fibers from tumor-induced wasting.
  34. (1977). Saxel O: Serial passaging and differentiation of myogenic cells isolated from dystrophic mouse muscle. Nature
  35. (1996). Skeletal muscle cells lacking the retinoblastoma protein display defects in muscle gene expression and accumulate in S and G2 phases of the cell cycle.
  36. (1972). Strohman RC: Myosin synthesis in cultures of differentiating chicken embryo skeletal muscle. Dev Biol
  37. (2007). Su Q: Inhibition of adenovirusmediated human MAGE-D1 on angiogenesis in vitro and in vivo. Mol Cell Biochem
  38. (2002). Tapscott SJ: Promoter-specific regulation of MyoD binding and signal transduction cooperate to pattern gene expression. Mol Cell
  39. (1990). The MyoD DNA binding domain contains a recognition code for muscle-specific gene activation. Cell
  40. (2008). The Prader-Willi syndrome protein necdin interacts with the E1A-like inhibitor of differentiation EID-1 and promotes myoblast differentiation. Differentiation
  41. (2008). Trouche D: Binding of the retinoblastoma protein is not the determinant for stable repression of some E2F-regulated promoters in muscle cells. Mol Cancer Res
  42. (2001). Watanabe K: Dlxin-1, a novel protein that binds Dlx5 and regulates its transcriptional function.
  43. (2006). WH: Loss of myogenin in postnatal life leads to normal skeletal muscle but reduced body size. Development

To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.